This study aims to develop and validate a multiregional radiomics model to predict pathological complete response (pCR) to neoadjuvant chemoimmunotherapy in non-small cell lung cancer (NSCLC), and further evaluate the performance of the model in different specific subgroups (N2 stage and anti-PD-1/PD-L1).

Read the full article on ejradiology.com